


Subcommittee Plasma Cell Disorders

Chair: Stefan Schönland, Vice-Chair: Meral Beksac

Overview of registered MM patients



Proposed studies

Impact of high-risk genetic aberrations on outcome after salvage autoHSCT in relapsed MM

This retrospective study aims at investigating the outcome of salvage autoHSCT of MM patients with high-risk genetic aberrations at diagnosis. A special focus will be on salvage autoHSCT before or after the approval of novel agents including IMiDs and proteasome inhibitors.

Outcomes of conditioning following addition of novel agents to high dose Melphalan during autoHSCT in MM

The aim of this study is to evaluate if intensification of conditioning following addition of novel agents to high dose Melphalan during autoHSCT in MM will improve survival outcomes of patients. The study will compare patients who received novel agents to those who did not.

Data request

AutoHSCT for relapsed MM performed with cells procured after a previous autoHSCT

This retrospective analysis covers patients who underwent - after a previous autologous hematopoietic stem cell transplantation - a remobilization of stem cells and salvage autoHSCT performed with use of these remobilized cells. The primary objective is to provide data on the feasibility of such a stem cell remobilization, as well as to provide data on the short- and long-term efficacy and safety of salvage autoHSCT performed with cells remobilized after a previous autoHSCT.

Practice Harmonisation and Guidelines

Chair: Patrick Hayden, Vice-chair: Laurent Garderet

Last year, the CMWP has instituted a Practice Harmonisation and Guidelines subcommittee with the intention to produce practical clinically relevant guidelines for haematologists in the field of HSCT.

First project initiated

Management of adults and children undergoing autologous CAR T-cell therapy: Recommendations of the EBMT

Following discussion at recent working party meetings, it was felt that there was a need for EBMT guidelines on CAR T-cell therapy. These recommendations are intended to be general in scope and to be applicable to any given disease or type of CAR T-cell therapy. As these guidelines will span the activities of most of the working parties, this is therefore a shared EBMT project.

Next business meetings

Monday March 25th 07:00-09:00, Illusion 2
EBMT Congress 2019, Frankfurt, Germany


Friday 4th – Sunday 6th October, 2019

Business meeting, Istanbul, Turkey

Subcommittee Chronic Lymphocytic Leukemia

Chair: Olivier Tournilhac, Vice-chair: Michel van Gelder

Overview of registered CLL patients



Proposed studies

AlloHSCT for CLL in the context of Venetoclax treatment

Venetoclax is used as salvage after BTKi failure. We aim to retrospectively study Venetoclax use either as a bridge to alloHSCT and/or as a post-alloHSCT strategy. The focus will be on the prior treatment pedigree, response status pre-alloHSCT and impact on specific outcomes (e.g. GVHD, infection).

AlloHSCT for Richter Syndrome (RS)

Richter Syndrome after both BTKi and BCL2i treatments has a poor prognosis. This retrospective study aims at collecting data on alloHSCT in Richter Syndrome within the last 10 years. Documented histology will be verified before case inclusion.

AlloHSCT for B-prolymphocytic leukemia (B-PLL)

B-PLL has a high occurrence of TP53 disruption, cMyc activation (or both) and a poor prognosis. There is no evidence that BCRi and/or BCL2i can produce long term control in B-PLL. Hence, alloHSCT remains a valid option and will be evaluated in this retrospective study. For this study, centers will be asked to confirm the diagnosis of B-PLL.

Long term analysis of alloHSCT for T-prolymphocytic leukemia (T-PLL)

The only curative strategy in T-PLL is alloHSCT. Yet, it has a high relapse rate. This long-term analysis will focus on late relapse incidence and management.

Oral Session 12: Multiple Myeloma

Wednesday March 27th 09:00–10:30, Conclusio 1 + 2

09:11–09:22 OS12-2: Impact of high-risk cytogenetics in newly diagnosed multiple myeloma undergoing upfront stem cell transplantation: a study from the EBMT Chronic Malignancies Working Party – Nico Gagelmann

09:33–09:44 OS12-4: The role of renal impairment at diagnosis in multiple myeloma undergoing autologous transplantation: a retrospective analysis of the CMWP – Christof Scheid

09:44–09:55 OS12-5: Analysis of outcomes in patients with myeloma who had a second alloHSCT either for disease relapse or graft failure: an EBMT CMWP study – Patrick Hayden

Recently published articles

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.

Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schönland S, D'Souza A, Kröger N & Hari P. *Biology of Blood and Marrow Transplantation*. 2019 Feb;25(2):335-342. doi:10.1016/j.bbmt.2018.09.018.

Impact of Extramedullary Disease in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Study from the Chronic Malignancies Working Party of the EBMT.

Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pionelli P, Snowden JA, Itälä-Remes M, Musso M, van Biezen A, Garderet L & Kröger N. *Haematologica*. 2018 May;103(5):890-897. doi:10.3324/haematol.2017.178434.

Ibrutinib for Bridging to Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenbergh E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussière-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Caneparo ME, Schaap M, Fox CP, Kröger N, Montoto S & Schetelig J. *Bone Marrow Transplantation*. 2018 May 4. doi:10.1038/s41409-018-0207-4 [Epub ahead of print].

Outcomes of Haploidentical Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT.

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foà R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J & Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transplantation*. 2018 Mar;53(3):255-263. doi:10.1038/s41409-017-0023-2.

EBMT Prospective Observational Study on Allogeneic Hematopoietic Stem Cell Transplantation in T-Prolymphocytic Leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foà R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N & Dreger P. *Bone Marrow Transplantation*. 2019 Jan 21. doi:10.1038/s41409-019-0448-x [Epub ahead of print].